Compare iShares Bitcoin Trust (IBIT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Bitcoin Trust trades at $45.99 (market cap $66.43B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Bitcoin Trust is far larger — about 8.8× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 42 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IBIT | SYRE | |
|---|---|---|
Market Cap | $66.43B | $7.52B |
Volume | 28,050,093 | 1,441,031 |
Sector | Crypto-linked | Health |
52-Week High | $65.28 | $108.92 |
52-Week Low | $33.29 | $22.18 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.13, up 0.58% with neutral technical signals overall. The stock shows bullish moving average momentum but mixed oscillators, with key support at $46 and resistance at $48. Recent institutional inflows and positive ETF performance highlight growing investor interest in BlackRock's Bitcoin trust vehicle, though financial ratios remain undisclosed in current filings.
Outlook remains cautiously optimistic given strong institutional inflows and market positioning. Key risks include regulatory uncertainty and Bitcoin price volatility affecting the trust's underlying value. Analyst sentiment appears balanced with technical indicators suggesting near-term consolidation around current levels.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
